On Nov 22, BILBREY JOHN P, Director bought 3,766 shares of Elanco Animal Health Incorporated (NYSE: ELAN), with the average selling price of the stock being $26.58 per share. The total amount realized from this purchase $100,100. A document was filed with the Securities and Exchange Commission to notify the public about the purchase of the shares.
In addition to that, See Remarks – Urbanek David Alan bought an extra 228 shares of this stock in a transaction that took place a day before, on Nov 18, with a share bought at an average of $26.26 and a total of $5,986 was realized from this transaction. After the transaction, the See Remarks – Urbanek David Alan was left with 76 shares of the company’s stock, which is currently worth around $1995.76.
The recent price movement of ELAN means that it is now down by -23.41% from its 52-week high and 7.56% up against its 52-week low prices. Over the past one week, the price volatility of ELAN stands at 1.60% while the volatility over the past one month is 2.83%.
The company on 11/06/2019 published its latest quarterly earnings, with the report showing that the company recorded 0.29 earnings per share (EPS) during that period. This report was above the expectations of analysts of 0.28 by 0.01. The revenue by the firm was 793.66M for the quarter.
The shares of Elanco Animal Health Incorporated (ELAN) dropped by -0.04%, leading to a loss of -$0.01 per share, and saw ELAN end the trading session at $27.16 on Thursday 12/05/19. ELAN started the trading session at $27.16, before reaching a daily high of $27.24. It wasn’t able to sustain that growth though and soon jumped to hit a daily low of $26.7427.
The trading volume on Thursday stood at 1796498, which was below the stock’s 3-month average volume of 3.81 million shares, out of a total 371.97M shares. As the price of the stock dipped, the market valuation of the company dropped to 10.19 billion.
The shares of Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) went down by -0.30% by the end of the recent trading session. This movement saw its price plunge to close at $10.02, which was lower than the previous closing price of $10.05. Over the past one week, the price of MDRX has slipped by -7.82%, while it has recorded a loss of -11.72% over the past one month. Its three-month performance saw MDRX gain 8.91% while its six-month performance saw it drop by -3.09%. The situation is different though over the past one year, as the stock price went up by 2.04%, while its year-to-date (YTD) price performance jumped by 3.94%. The stock price has gone up by +9.21% compared to its 90-day low, while it is down -15.23% compared to its 90-day high price.
Let’s take a look at its short, medium and long-term indicators. Composite Indicators shows that Trendspotter rated the stock as a Sell. In the short-term, the stock has a 20-day average volume of 2,015,140 shares, with the short-term indicators averagely rating the stock as a Hold. A look at its medium-term indicators reveals that it has a 50-Day average volume of 1,741,528 shares and the indicators have an average rating of 50% Buy. The last indicators, the long-term see MDRX stock with a 100-Day average volume of 1,797,890 shares, giving it an average rating of 75% Sell. A look at the general picture of all short, medium and long-term indicators leaves MDRX with an average rating of 16% Sell.
Several brokerage firms sent out their reports MDRX stock not long ago. In its report sent out on November 26, 2019, UBS lowered its ratings on MDRX to a Neutral. In an earlier report on September 26, 2019, Deutsche Bank Initiated the stock to a Hold. KeyBanc Capital Markets meanwhile in its report on February 22, 2019 Downgrade its rating of the stock from a “Sector Weight” to “Sector Weight”.
In a recent SEC filing, the company revealed that 249 institutions currently hold the MDRX stock. In the last quarter, a 179,525,442 MDRX shares were in the possession of institutions. On the other hand, the company recorded 23 new institutions who bought it their stock, while 30 institutions sold their entire MDRX reserve. Of the current institutions investing in the stock, 100 increased their investment while 112 decreased their investment in the stock.